ArcticZymes Technologies — Regulatory Filings 2016

Jun 13, 2016

Enters into German distribution agreement for Woulgan®

Enters into German distribution agreement for Woulgan®

(Tromsø, 13 June 2016) Biotec Pharmacon ASA ("Biotec", OSE: BIOTEC) has entered

into a distribution agreement for Woulgan® with the German distributor Rogg

Verbandstoffe GmbH (Rogg).

-Biotec is pleased to announce Rogg as the first German distribution partner of

Woulgan®. The agreement is in line the Biotec's outlook to secure one or more

distribution agreement in Germany during 2016. With its 20 sales reps, Rogg is

well positioned to succeed with Woulgan® in their focused segments and we look

forward to start the co-operation, says Svein Lien, CEO of Biotec Pharmacon.

Woulgan® is a premium priced product targeting hard to heal wounds in the

professional wound care market. Clinical experience with Woulgan® demonstrate

significantly improved healing, less pain and improved comfort during the

treatment period compared to most common therapies.

Rogg is a German company founded in 1970 and is one of Germany's leading

suppliers of wound care products to the health sector. The company is primarily

supplying physician offices and pharmacies, which are important segments for

Woulgan®. Rogg is owned and run by Prof. Dr. Dr Ulrich Hemel, who has a long

track record managing wound care companies.

-Woulgan® is an exciting product with a lot of potential that is going to be

interesting to work with going forward. Woulgan will be a prioritized product in

our product portfolio, and will strengthen our position within the professional

wound care market. We are eager to get started securing a strong position for

Woulgan in the German market, says Prof. Dr. Dr.Ulrich Hemel, CEO of Rogg

Verbandstoffe.

Under the terms of the agreement, Rogg becomes a preferred partner for

distribution to physician offices and pharmacies, which means Biotec will avoid

conflicting distribution to these segments, while distribution to hospitals and

home care providers are not part of the agreement. The agreement has an initial

term of one year with the aim to prolong it into a longer term agreement

thereafter. Biotec will support Rogg through its marketing division and expects

limited costs to incur.

For additional information,

Svein Lien, CEO

+47 922 89 323

svein.lien@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, a premium priced product in the

advanced wound care market. ArcticZymes develops, produces and markets enzymes

of marine origin used in molecular DNA technologies and diagnostics.

About Rogg Verbandstoffe GmbH& Co.KG

Rogg Verbandstoffe GmbH&Co.KG stands for "Healthy innovation" and has achieved a

position as one of the most innovative providers for Modern Wound Care in

Germany including a wide portfolio of products in the field of bandages,

dressings, and disinfection. The company has a sales force covering all German

regions and a large experience in marketing new and innovative products such as

Biotec's Woulgan®.